AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Detection of HBx/8p11 Hybrid Sequence in Human Hepatocellular Carcinoma

Summary

‘The Invention’ described here is directed to a hybrid RNA sequence of hepatitis B virus fused with human sequence that is not naturally occurring in the human genome. The hybrid sequence is transcribed from the tumor genome of hepatocellular carcinoma as a result of hepatitis B virus integration. Specifically, ‘The Invention’ is a chimeric RNA sequence of 674 nucleotides that comprised of sequences from the hepatitis B virus and the human chr.8p11 intergenic region. ‘The Invention’ being the HBx/8p11 transcript can be detected in 24.4% of hepatitis B virus related hepatocellular carcinoma, and hold prognostic value in predicting shorter patient survival. The presence of the HBx/8p11 transcript is useful in detecting tumor growth, cell invasion and migratory properties of hepatocellular carcinoma.

The discovery of HBx/8p11 chimeric transcript in ~25% of hepatitis B virus related hepatocellular carcinoma is useful for a variety of diagnostic and therapeutic applications. The HBx/8p11 transcript has the advantage in predicting aggressive tumor properties of hepatocellular carcinoma, and the effect can be inhibited by anti-sense treatment.

Supplementary Information

Patent Number: US8680255B2
Application Number: US13599741A
Inventor: Wong, Nathalie
Priority Date: 1 Sep 2011
Priority Number: US8680255B2
Application Date: 30 Aug 2012
Publication Date: 25 Mar 2014
IPC Current: C12Q000168
US Class: 5360231 | 43500614 | 5360243 | 536023 | 536024
Assignee Applicant: The Chinese University of Hong Kong
Title: Detection of HBX/8P11 hybrid sequence in human hepatocellular carcinoma
Usefulness: Detection of HBX/8P11 hybrid sequence in human hepatocellular carcinoma
Summary: The methods and kit are used for assessing the presence or risk of HBx/8p11-positive human HCC and for treating HBx/8p11-positive human HCC (all claimed).
Novelty: Assessing the presence or risk of HBx/8p11-positive human hepatocellular carcinoma comprises detecting HBx/8p11 hybrid sequence in a test sample

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Application No.

11/MED/426

Others

Inventor(s): Professor Nathalie WONG, Dept of Anatomical and Cellular Pathology Licensing Status: Available

Country/Region

Hong Kong

For more information, please click Here